1 Min Read
Dec 4 (Reuters) - Moleculin Biotech Inc:
* MOLECULIN BIOTECH SAYS ON NOV 29, CO WAS INFORMED THAT INVESTIGATIONAL NDA FOR PHASE I TRIAL OF WP1066 HAS BEEN ALLOWED BY FDA - SEC FILING Source text: [bit.ly/2jcVpeo] Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.